

---

**CAMBRIDGE EYE CLINIC LIMITED**

---

**UNAUDITED**

**FINANCIAL STATEMENTS**

**INFORMATION FOR FILING WITH THE REGISTRAR**

**FOR THE YEAR ENDED 31 MARCH 2023**

**CAMBRIDGE EYE CLINIC LIMITED**  
**REGISTERED NUMBER: 05780109**

**BALANCE SHEET**  
**AS AT 31 MARCH 2023**

	Note	2023 £	2023 £	2022 £	2022 £
<b>FIXED ASSETS</b>					
Tangible assets	4		2,295		5,022
<b>CURRENT ASSETS</b>					
Debtors: amounts falling due within one year	5	28,436		52,018	
Cash at bank and in hand		985,815		768,528	
		<u>1,014,251</u>		<u>820,546</u>	
Creditors: amounts falling due within one year	6	(88,723)		(109,758)	
<b>NET CURRENT ASSETS</b>			925,528		710,788
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<u>927,823</u>		<u>715,810</u>
<b>PROVISIONS FOR LIABILITIES</b>					
Deferred tax	7	(574)		(1,256)	
			<u>(574)</u>		<u>(1,256)</u>
<b>NET ASSETS</b>			<u>927,249</u>		<u>714,554</u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital	8		2		2
Profit and loss account			927,247		714,552
			<u>927,249</u>		<u>714,554</u>

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

---

**CAMBRIDGE EYE CLINIC LIMITED**  
**REGISTERED NUMBER: 05780109**

---

**BALANCE SHEET (CONTINUED)**  
**AS AT 31 MARCH 2023**

---

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

**C G Stephenson**  
**Director**

Date: 14 August 2023

The notes on pages 3 to 6 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2023**

---

**1. GENERAL INFORMATION**

Cambridge Eye Clinic Limited is a private company limited by shares and incorporated in England and Wales. Its registered office is Salisbury House, Station Road, Cambridge, CB1 2LA.

The principal place of business is 36 Northrop Road, Trumpington, Cambridge, CB2 9DD.

The Company's functional and presentational currency is GBP.

**2. ACCOUNTING POLICIES**

**2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS**

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

**2.2 TURNOVER**

Turnover comprises revenue recognised by the Company in respect of specialist clinical ophthalmology services during the year, exclusive of Value Added Tax. Revenue is recognised as the fair value of the consideration received or receivable and is recognised based on the date the work was performed.

**2.3 CURRENT AND DEFERRED TAXATION**

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2023

---

**2. ACCOUNTING POLICIES (CONTINUED)**

**2.4 PENSIONS**

The Company contributes to the personal pension plan of one of the directors. Contributions are recognised in the year in which they are paid.

**2.5 TANGIBLE FIXED ASSETS**

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment	-	33%
------------------	---	-----

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

**2.6 DEBTORS**

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

**2.7 CASH AND CASH EQUIVALENTS**

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

**2.8 CREDITORS**

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

**2.9 DIVIDENDS**

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2023

3. EMPLOYEES

The average monthly number of employees, including directors, during the year was 2 (2022 - 2).

4. TANGIBLE FIXED ASSETS

	Office equipment £
<b>COST OR VALUATION</b>	
At 1 April 2022	8,186
At 31 March 2023	8,186
<b>DEPRECIATION</b>	
At 1 April 2022	3,164
Charge for the year on owned assets	2,727
At 31 March 2023	5,891
<b>NET BOOK VALUE</b>	
At 31 March 2023	2,295
At 31 March 2022	5,022

5. DEBTORS

	2023 £	2022 £
Trade debtors	28,436	35,976
Prepayments and accrued income	-	16,042
	<u>28,436</u>	<u>52,018</u>

**CAMBRIDGE EYE CLINIC LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2023**

**6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023 £	2022 £
Corporation tax	76,476	89,841
Other creditors	8,271	15,764
Accruals and deferred income	3,976	4,153
	<u>88,723</u>	<u>109,758</u>

**7. DEFERRED TAXATION**

	2023 £	2022 £
At beginning of year	(1,256)	(609)
Charged to profit or loss	682	(647)
<b>AT END OF YEAR</b>	<u>(574)</u>	<u>(1,256)</u>

The provision for deferred taxation is made up as follows:

	2023 £	2022 £
Accelerated capital allowances	<u>(574)</u>	<u>(1,256)</u>

**8. SHARE CAPITAL**

	2023 £	2022 £
<b>ALLOTTED, CALLED UP AND FULLY PAID</b>		
90 (2022 - 90) Ordinary shares of £0.01 each	0.90	0.90
90 (2022 - 90) A Ordinary shares of £0.01 each	0.90	0.90
20 (2022 - 20) B Ordinary shares of £0.01 each	0.20	0.20
	<u>2.00</u>	<u>2.00</u>





This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.